SUNPHARMASun Pharmaceutical Industries Ltd.

    Sun Pharmaceutical Industries Ltd: results and news

    Every Sun Pharmaceutical Industries Ltd filing with the NSE and BSE that Blacklitt has written about, explained in plain words and linked to the filing, newest first: exchange query, credit rating, earnings.

    4 articles · Pharmaceuticals · Latest 6 Nov 2026

    A pile of white tablets and green and orange capsules with a glass thermometer lying across them.

    SUNPHARMASun Pharmaceutical Industries Ltd.

    Sun Pharmaceutical Industries Q2 FY27 Results: Consolidated Net Profit ₹1,995 Crore on Total Income of ₹16,716 Crore

    Sun Pharmaceutical Industries reported consolidated total income of ₹16,716.03 crore and net profit of ₹1,995.07 crore for the quarter ended 30 Sep 2026. On a standalone basis, total income was ₹6,222.93 crore and net profit ₹871.29 crore. The company said in a filing on 30 Oct 2026.

    • Earnings
    • pharmaceuticals

    Blacklitt Research4 min read

    A pile of assorted tablets and capsules

    SUNPHARMASun Pharmaceutical Industries Ltd

    CRISIL and ICRA assign AAA ratings to Sun Pharma’s proposed NCDs, factoring in the planned Organon acquisition

    Sun Pharmaceutical Industries Limited has told the exchanges that CRISIL Ratings and ICRA have assigned ratings to its proposed non-convertible debenture (NCD) programme and reaffirmed the ratings on its existing facilities. CRISIL has assigned Crisil AAA/Stable to ₹15,000 crore of proposed NCDs and reaffirmed Crisil A1+ on ₹4,000 crore of commercial paper and Crisil AAA/Stable/Crisil A1+ on ₹176 crore of bank facilities. ICRA has assigned [ICRA]AAA (Stable) to the proposed NCDs and reaffirmed [ICRA]A1+ on commercial paper and [ICRA]AAA (Stable)/[ICRA]A1+ on its long-term and short-term limits.

    • Credit rating
    • Pharmaceuticals

    Blacklitt Research2 min read